• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Augmedix Inc.

    7/29/24 5:23:20 PM ET
    $AUGX
    Business Services
    Consumer Discretionary
    Get the next $AUGX alert in real time by email
    SC 13G 1 augx13g.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. ___)*

     

     

    Augmedix, Inc.

    (Name of Issuer)

     

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

     

    05105P107

    (CUSIP Number)

     

     

    July 19, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [X]       Rule 13d-1(b)

     

    [X]       Rule 13d-1(c)

     

    [ ]       Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     1 
    CUSIP No. 05105P107

     

     

    1.Names of Reporting Persons.


    Beryl Capital Management LLC

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)     X     

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 4,523,272

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 4,523,272

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 4,523,272

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 9.2%

     

    12. Type of Reporting Person (See Instructions) IA, OO

     2 
    CUSIP No. 05105P107

     

     

    1.Names of Reporting Persons.


    Beryl Capital Management LP

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)     X     

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 4,523,272

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 4,523,272

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 4,523,272

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 9.2%

     

    12. Type of Reporting Person (See Instructions) IA, PN

     3 
    CUSIP No. 05105P107

     

     

    1.Names of Reporting Persons.


    Beryl Capital Partners II LP

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)          

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 3,854,531

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 3,854,531

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 3,854,531

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 7.9%

     

    12. Type of Reporting Person (See Instructions) PN

     4 
    CUSIP No. 05105P107

     

    1.Names of Reporting Persons.


    David A. Witkin

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)     X     

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization U.S.A.

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 4,523,272

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 4,523,272

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 4,523,272

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 9.2%

     

    12. Type of Reporting Person (See Instructions) IN, HC

     5 
    CUSIP No. 05105P107

    Item 1.

     

    (a)Name of Issuer

    Augmedix, Inc.

     

    (b)Address of Issuer's Principal Executive Offices

    111 Sutter Street, Suite 1300, San Francisco, CA 94104

     

    Item 2.

     

    (a)The names of the persons filing this statement are:

    Beryl Capital Management LLC (“Beryl”), Beryl Capital Management LP (“Beryl GP”), Beryl Capital Partners II LP (the “Partnership”) and David A. Witkin (collectively, the “Filers”). Each Filer disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    (b)The principal business office of the Filers is located at:

    225 Avenue I, Suite 205, Redondo Beach, CA 90277

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s Common Stock, par value $0.0001 per share (the "Stock").

     

    (e)The CUSIP number of the Issuer is: 05105P107

     

     

     6 
    CUSIP No. 05105P107

     

    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)[X] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E), as to Beryl and Beryl GP.

     

    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

     

    (g)[X] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G), as to Mr. Witkin.

     

    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j)[ ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J).

     

    (k)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution _______________________________________________________________.

     

    Item 4.Ownership.

     

    See Items 5-9 and 11 of the cover page for each Filer.

     

    The percentages reported in this Schedule 13G are based on 48,967,729 shares of Common Stock outstanding as of May 10, 2024, as reported in the Form 10-Q filed by the Issuer on May 13, 2024.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Beryl is the investment adviser to the Funds and other accounts. Beryl is the general partner of Beryl GP, which is the general partner of one or more of the Funds. Mr. Witkin is the control person of Beryl.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Material to Be Filed as Exhibits

    Exhibit A Joint Filing Agreement.

    Item 11.Certification of Beryl, Beryl GP and Mr. Witkin.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Certification of the Partnership.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     7 
    CUSIP No. 05105P107

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: July 29, 2024

     

    BERYL CAPITAL MANAGEMENT LLC  

    BERYL CAPITAL MANAGEMENT LP

     

          By: Beryl Capital Management LLC
            General Partner
    By:  /s/ Andrew Nelson      
      Andrew Nelson     By: /s/ Andrew Nelson
      Chief Operating Officer and CFO       Andrew Nelson
            Chief Operating Officer and CFO
    BERYL CAPITAL PARTNERS II LP    
         
    By: Beryl Capital Management LP   /s/ David A. Witkin
    General Partner   David A. Witkin
         
    By: Beryl Capital Management LLC    
    General Partner    
         
    By:/s/ Andrew Nelson    
    Andrew Nelson    
    Chief Operating Officer    
     8 
    CUSIP No. 05105P107

     

    EXHIBIT A

     

    AGREEMENT REGARDING JOINT FILING

    OF STATEMENT ON SCHEDULE 13D OR 13G

     

    The undersigned agree to file jointly with the Securities and Exchange Commission (the "SEC") any and all statements on Schedule 13D or Schedule 13G and Forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Beryl Capital Management, LLC, a Delaware limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

     

     

    Dated: July 29, 2024

     

    BERYL CAPITAL MANAGEMENT LLC  

    BERYL CAPITAL MANAGEMENT LP

     

          By: Beryl Capital Management LLC
            General Partner
    By: /s/ Andrew Nelson      
      Andrew Nelson     By: /s/ Andrew Nelson
      Chief Operating Officer and CFO       Andrew Nelson
            Chief Operating Officer and CFO
    BERYL CAPITAL PARTNERS II LP    
         
    By: Beryl Capital Management LP   /s/ David A. Witkin
    General Partner   David A. Witkin
         
    By: Beryl Capital Management LLC    
    General Partner    
         
    By:/s/ Andrew Nelson    
    Andrew Nelson    
    Chief Operating Officer    

     

     

     

    Get the next $AUGX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AUGX

    DatePrice TargetRatingAnalyst
    7/22/2024Buy → Hold
    Lake Street
    7/22/2024$3.00 → $2.35Buy → Neutral
    B. Riley Securities
    5/14/2024$5.00Buy → Hold
    Maxim Group
    5/14/2024$5.00 → $1.50Outperform → In-line
    Evercore ISI
    4/3/2024$5.50Buy
    B. Riley Securities
    12/15/2023$6.00In-line
    Evercore ISI
    3/7/2022$6.00Buy
    Lake Street
    1/21/2022$6.00Buy
    Maxim Group
    More analyst ratings

    $AUGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Redmile Group, Llc returned $75,402,504 worth of shares to the company (32,086,172 units at $2.35) (SEC Form 4)

      4 - Augmedix, Inc. (0001769804) (Issuer)

      10/4/24 5:01:03 PM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • SEC Form 4 filed by Director Faulkner Robert C.

      4 - Augmedix, Inc. (0001769804) (Issuer)

      10/4/24 5:00:14 PM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Director Febbo William J returned $382,070 worth of shares to the company (162,583 units at $2.35), closing all direct ownership in the company (SEC Form 4)

      4 - Augmedix, Inc. (0001769804) (Issuer)

      10/4/24 1:17:00 PM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Commure Completes Merger with Augmedix

      SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Commure, a healthcare technology company, announced today that it has completed the acquisition of Augmedix. Augmedix will now operate as a wholly-owned subsidiary of Commure. The merger was previously announced on July 19, 2024, and was approved by Augmedix stockholders at Augmedix's special meeting of stockholders held on September 27, 2024. With the completion of the acquisition, Augmedix stockholders are entitled to $2.35 in cash for each share of Augmedix common stock they owned immediately prior to the closing. Augmedix's stock has ceased trading and will be delisted from the Nasdaq Stock Market. "I started Augmedix to relieve clinic

      10/2/24 8:23:42 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix Delivers 27% Revenue Growth for Second Quarter of 2024

      SAN FRANCISCO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended June 30, 2024. "We believe we are approaching the proposed combination with Commure, Inc. from a position of strength, with consistent double-digit revenue growth and improving gross margins," commented Manny Krakaris, Augmedix CEO. "Together, we believe we will be well-positioned to continue to streamline the medical documentation ecosystem with a growing base of health system customers, solid partners, and proven solutions. As part of Commure, we expect to scale our ambient documentation solu

      8/12/24 4:01:00 PM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix to Announce Second Quarter 2024 Financial Results on August 12, 2024

      SAN FRANCISCO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, announced today it anticipates releasing second quarter 2024 results after the market closes on Monday, August 12, 2024. On July 19, 2024, Augmedix announced that it entered into a definitive agreement to be acquired by Commure, Inc., a leading provider of technology to healthcare systems. Due to this pending acquisition, management is not hosting a quarterly conference call. About Augmedix Augmedix (NASDAQ:AUGX) empowers clinicians to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and

      8/6/24 7:00:00 AM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Augmedix downgraded by Lake Street

      Lake Street downgraded Augmedix from Buy to Hold

      7/22/24 8:25:03 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix downgraded by B. Riley Securities with a new price target

      B. Riley Securities downgraded Augmedix from Buy to Neutral and set a new price target of $2.35 from $3.00 previously

      7/22/24 8:02:58 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix downgraded by Maxim Group with a new price target

      Maxim Group downgraded Augmedix from Buy to Hold and set a new price target of $5.00

      5/14/24 8:17:17 AM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ginocchio Paul bought $48,500 worth of shares (10,000 units at $4.85), increasing direct ownership by 8% to 128,000 units (SEC Form 4)

      4 - Augmedix, Inc. (0001769804) (Issuer)

      11/27/23 7:00:06 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Redmile Group, Llc bought $6,000,000 worth of shares (1,500,000 units at $4.00) (SEC Form 4)

      4 - Augmedix, Inc. (0001769804) (Issuer)

      11/22/23 4:15:24 PM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Augmedix Inc.

      15-12G - Augmedix, Inc. (0001769804) (Filer)

      10/15/24 9:32:28 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • SEC Form EFFECT filed by Augmedix Inc.

      EFFECT - Augmedix, Inc. (0001769804) (Filer)

      10/4/24 12:15:04 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • SEC Form EFFECT filed by Augmedix Inc.

      EFFECT - Augmedix, Inc. (0001769804) (Filer)

      10/4/24 12:15:02 AM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    Leadership Updates

    Live Leadership Updates

    See more
    • Augmedix to Join Forces with Commure

      SAN FRANCISCO, July 19, 2024 (GLOBE NEWSWIRE) -- Augmedix, Inc. (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today announced that it has entered into a definitive agreement to be acquired by Commure, Inc., a leading provider of technology to healthcare systems, in an all-cash transaction that values Augmedix at approximately $139 million in equity value. Under the terms of the agreement, Augmedix stockholders will receive $2.35 per share in cash upon completion of the proposed transaction, and Augmedix will become a wholly-owned subsidiary of Commure. The purchase price represents a premium of approximately 169% over the volume weighted average price

      7/19/24 7:00:00 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix Appoints Alex Stinard, M.D., as Chief Clinical AI Officer

      SAN FRANCISCO, May 29, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient artificial intelligence (AI) medical documentation and data solutions, today announced that Alex Stinard, M.D., has been named Chief Clinical AI Officer of the company. Dr. Stinard brings over two decades of extensive experience as an emergency medicine clinician. He has a background in data science with a specialization in large language models, computer vision, and natural language processing. This mix of experience makes Dr. Stinard uniquely qualified for this new position. "Welcoming Dr. Stinard to join Augmedix in this new role is an exciting step forward in implementing advanced AI technolog

      5/29/24 7:00:00 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix and SADA Forge Partnership to Scale Ambient Documentation and Structured Data Products to Health Systems Nationwide

      SAN FRANCISCO, April 04, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today announced its go-to-market partnership with SADA, an Insight company, a leading cloud business and technology consultancy. The collaboration is focused on leveraging the companies' combined technology expertise and expanding their reach to provide greater product and service value to health systems seeking high-quality ambient documentation and structured data products. "We are thrilled to join forces with SADA, to partner with an organization that has a nationwide reach to health systems, and also to leverage their prowess in frontier cloud infr

      4/4/24 7:00:00 AM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    Financials

    Live finance-specific insights

    See more
    • Commure Completes Merger with Augmedix

      SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Commure, a healthcare technology company, announced today that it has completed the acquisition of Augmedix. Augmedix will now operate as a wholly-owned subsidiary of Commure. The merger was previously announced on July 19, 2024, and was approved by Augmedix stockholders at Augmedix's special meeting of stockholders held on September 27, 2024. With the completion of the acquisition, Augmedix stockholders are entitled to $2.35 in cash for each share of Augmedix common stock they owned immediately prior to the closing. Augmedix's stock has ceased trading and will be delisted from the Nasdaq Stock Market. "I started Augmedix to relieve clinic

      10/2/24 8:23:42 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix to Announce Second Quarter 2024 Financial Results on August 12, 2024

      SAN FRANCISCO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, announced today it anticipates releasing second quarter 2024 results after the market closes on Monday, August 12, 2024. On July 19, 2024, Augmedix announced that it entered into a definitive agreement to be acquired by Commure, Inc., a leading provider of technology to healthcare systems. Due to this pending acquisition, management is not hosting a quarterly conference call. About Augmedix Augmedix (NASDAQ:AUGX) empowers clinicians to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and

      8/6/24 7:00:00 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix Delivers 40% Revenue Growth for First Quarter of 2024

      SAN FRANCISCO, May 13, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended March 31, 2024. "Augmedix delivered in-line first quarter performance, with 40% revenue growth, 143% net revenue retention and 47.1% gross margins," commented Manny Krakaris, Augmedix CEO. "We are confident about our positioning within the medical documentation market, and expect to report continued growth throughout the rest of the year. It is now clear, however, that health systems are proceeding methodically while they develop a better understanding of the capabilities of AI products." "We a

      5/13/24 4:03:00 PM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Augmedix Inc.

      SC 13D/A - Augmedix, Inc. (0001769804) (Subject)

      10/4/24 5:00:14 PM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • SEC Form SC 13G filed by Augmedix Inc.

      SC 13G - Augmedix, Inc. (0001769804) (Subject)

      7/29/24 5:23:20 PM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Amendment: SEC Form SC 13D/A filed by Augmedix Inc.

      SC 13D/A - Augmedix, Inc. (0001769804) (Subject)

      7/19/24 7:45:47 PM ET
      $AUGX
      Business Services
      Consumer Discretionary